[Federal Register: January 26, 2010 (Volume 75, Number 16)]
[Notices]
[Page 4063-4064]
[DOCID:fr26ja10-50]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-R05-OAR-2008-0682; FRL-9106-5]

Adequacy Status of the Cleveland/Akron, Ohio Submitted Annual
Fine Particulate Matter Attainment Demonstration for Transportation
Conformity Purposes

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of adequacy.

-----------------------------------------------------------------------

SUMMARY: In this notice, EPA is notifying the public that we have found
that the motor vehicle emissions budgets (MVEBs) for fine particulate
matter (PM2.5) and oxides of nitrogen (NOX) as a
precursor to fine particulate matter in the Cleveland/Akron, Ohio area
are adequate for use in transportation conformity determinations. Ohio
submitted the Cleveland/Akron area budgets with the attainment
demonstration submittal initially on July 16, 2008, and subsequently
submitted the public hearing results on December 5, 2008. As a result
of our finding, the Cleveland/Akron, Ohio area must use the MVEBs from
the submitted PM2.5 attainment demonstration plan for future
transportation conformity determinations.

DATES: This finding is effective February 10, 2010.

FOR FURTHER INFORMATION CONTACT: Patricia Morris, Environmental
Scientist, Criteria Pollutant Section (AR-18J), Air Programs Branch,
Air and Radiation Division, United States Environmental Protection
Agency, Region 5, 77 West Jackson Boulevard, Chicago, Illinois 60604,
(312) 353-8656<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Throughout this document, whenever ``we'',
``us'' or ``our'' is used, we mean EPA.

Background

    Today's notice is simply an announcement of a finding that we have
already made. On December 7, 2009, EPA Region 5 sent a letter to the
Ohio Environmental Protection Agency stating that the 2009 MVEBs for
the Cleveland/Akron, Ohio area, which were submitted with the state's
PM2.5 attainment demonstration, are adequate. Receipt of
these MVEBs was announced on EPA's transportation conformity Web site,
and no comments were submitted. The finding is available at EPA's
conformity Web site: http://www.epa.gov/otaq/stateresources/transconf/
adequacy.htm.
    The adequate 2009 MVEBs, in tons per year (tpy), for
PM2.5 and NOX for the Cleveland/Akron, Ohio area
are as follows:

                          Cleveland/Akron, Ohio
------------------------------------------------------------------------
                                          PM2.5 (tpy)       NOX (tpy)
------------------------------------------------------------------------
2009..................................          818.11         43553.48
------------------------------------------------------------------------

    Transportation conformity is required by section 176(c) of the
Clean Air Act. EPA's conformity rule requires that transportation
plans, programs, and projects conform to state air quality
implementation plans and establishes the criteria and procedures for
determining whether or not they do

conform. Conformity to a State Implementation Plan (SIP) means that
transportation activities will not produce new air quality violations,
worsen existing violations, or delay timely attainment of the national
ambient air quality standards.
    The criteria by which we determine whether a SIP's motor vehicle
emission budgets are adequate for transportation conformity purposes
are outlined in 40 CFR 93.118(e)(4). We have described our process for
determining the adequacy of submitted SIP budgets in our July 1, 2004
preamble starting at 69 FR 40038, and we used the information in these
resources while making our adequacy determination. Please note that an
adequacy review is separate from EPA's completeness review, and it also
should not be used to prejudge EPA's ultimate approval of the SIP. Even
if we find a budget adequate, the SIP could later be disapproved.
    The finding and the response to comments are available at EPA's
transportation conformity Web site: http://www.epa.gov/otaq/
stateresources/transconf/adequacy.htm.

    Authority: 42 U.S.C. 7401-7671q.

    Dated: January 13, 2010.
Walter W. Kovalick Jr.,
Acting Regional Administrator, Region 5.
[FR Doc. 2010-1462 Filed 1-25-10; 8:45 am]
BILLING CODE 6560-50-P


<!DOCTYPE HTML PUBLIC "-//-//W3C//DTD HTML 3.2//EN">

<META name="generator" content="PDFCreactiveX HTML Export">
<META name="creation-date" content="23/07/2008 11:06:21 ">
<TITLE></TITLE>


[Federal Register Volume 86, Number 192 (Thursday, October 7, 2021)]
[Notices]
[Pages 55846-55847]
[FR Doc No: 2021-22037]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-N-0965]

Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting; Establishment of a Public Docket; Request for
Comments

AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) announces a
forthcoming public advisory committee meeting of the Vaccines and
Related Biological Products Advisory Committee. The general function of
the committee is to provide advice and recommendations to the Agency on
FDA's regulatory issues. Members will participate via teleconference.
The meeting will be open to the public. FDA is establishing a docket
for public comment on this document.

DATES: The meeting will be held on October 14 through 15, 2021, from
8:30 a.m. to 5 p.m. Eastern Time. Submit either electronic or written
comments on this public meeting by October 13, 2021. Comments received
on or before October 12, 2021, will be provided to the committee.
Comments received after October 12, 2021, and by October 13, 2021, will
be taken into consideration by FDA.

ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. The online
web conference meeting will be available at the following separate
links on the days of the meeting:
    Day 1: https://youtu.be/BhlshZ7Lkr0.
    Day 2: https://youtu.be/c-H40GrvWz4.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2021-N-0965. The docket will close on October
13, 2021. Please note that late, untimely filed comments will not be
considered. The https://www.regulations.gov electronic filing system
will accept comments until 11:59 p.m. Eastern Time at the end of
October 13, 2021. Comments received by mail/hand delivery/courier (for
written/paper submissions) will be considered timely if they are
received on or before that date.
    In the event that the meeting is canceled, FDA will continue to
evaluate any relevant applications, submissions, or information, and
consider any comments submitted to the docket, as appropriate.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2021-N-0965 for ``Vaccines and Related Biological Products; Notice
of Meeting; Establishment of a Public Docket; Request for Comments.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Prabhakara Atreya or Kathleen Hayes,
Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 6306, Silver
Spring, MD 20993-0002,<PHONE_NUMBER>, via email at
<EMAIL_ADDRESS>or FDA Advisory Committee Information Line, 1-
800-741-8138<PHONE_NUMBER> in the Washington, DC area). A notice in the
Federal Register about last-minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's website at https://www.fda.gov/advisory-committees and scroll down to the appropriate advisory
committee meeting link, or call the

advisory committee information line to learn about possible
modifications before joining the meeting.

SUPPLEMENTARY INFORMATION: Consistent with FDA's regulations, this
notice is being published with less than 15 days prior to the date of
the meeting based on a determination that convening a meeting of the
Vaccines and Related Biological Products Advisory Committee as soon as
possible is warranted. This Federal Register notice could not be
published 15 days prior to the date of the meeting due to recent
requests to amend the Emergency Use Authorization (EUA) of the Moderna
COVID-19 mRNA vaccine for the administration of a booster dose,
following completion of the primary series, to individuals 18 years of
age and older, and also the EUA of the Janssen Biotech Inc. COVID-19
vaccine for the administration of a booster dose, to individuals 18
years of age and older, and the need for prompt discussion of such
requests given the COVID-19 pandemic.
    Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. On October
14, 2021, under Topic 1, the committee will meet in open session to
discuss the EUA of the Moderna COVID-19 mRNA vaccine for the
administration of a booster dose, following completion of the primary
series, to individuals 18 years of age and older. On October 15, 2021,
under Topic II, the committee will meet in open session to discuss the
EUA of the Janssen Biotech Inc. COVID-19 vaccine for the administration
of a booster dose, to individuals 18 years of age and older.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, background
material will be made publicly available on FDA's website at the time
of the advisory committee meeting. Background material and the link to
the online teleconference meeting room will be available at https://www.fda.gov/advisory-committees/advisory-committee-calendar. Scroll
down to the appropriate advisory committee meeting link. The meeting
will include slide presentations with audio components to allow the
presentation of materials in a manner that most closely resembles an
in-person advisory committee meeting.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see
ADDRESSES) on or before October 12, 2021, will be provided to the
committee. Comments received after October 12, 2021, and by October 13,
2021, will be taken into consideration by FDA. Oral presentations from
the public will be scheduled approximately between 12:45 p.m. and 1:45
p.m. Eastern Time on October 14, 2021, and approximately between 11
a.m. and 12 noon Eastern Time on October 15, 2021. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before 6 p.m. October 8,
2021. Time allotted for each presentation may be limited. If the number
of registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by October 12, 2021.
    For press inquiries, please contact the Office of Media Affairs at
<EMAIL_ADDRESS>or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Prabhakara Atreya or Kathleen Hayes<EMAIL_ADDRESS>at
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at: https://www.fda.gov/advisory-committees/about-advisory-committees/public-conduct-during-fda-advisory-committee-meetings for procedures on public conduct during
advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: October 5, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-22037 Filed 10-5-21; 4:15 pm]
BILLING CODE 4164-01-P


[Federal Register Volume 87, Number 16 (Tuesday, January 25, 2022)]
[Notices]
[Pages 3817-3818]
[FR Doc No: 2022-01368]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0031]

Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting; Establishment of a Public Docket; Request for
Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Vaccines and Related
Biological Products Advisory Committee. The general function of the
committee is to provide advice and recommendations to FDA on regulatory
issues. The meeting will be open to the public. FDA is establishing a
docket for public comment on this document.

DATES: The meeting will be held on March 3, 2022, from 9 a.m. to 3:30
p.m. Eastern Time.

ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions, including information regarding special
accommodations due to a disability, visitor parking, and
transportation, may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm. The online
web conference meeting will be available at the following link on the
day of the meeting: https://youtu.be/7fIEUdmn3AU.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2022-N-0031. The docket will close on March 2,
2022. Submit either electronic or written comments on this public
meeting by March 2, 2022. Please note that late, untimely filed
comments will not be considered. Electronic comments must be submitted
on or before February 23, 2022. The https://www.regulations.gov
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of February 23, 2022. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are postmarked or the delivery service acceptance
receipt is on or before that date.
    Comments received on or before February 23, 2022, will be provided
to the committee. Comments received after that date will be taken into
consideration by FDA. In the event that the meeting is cancelled, FDA
will continue to evaluate any relevant applications or information, and
consider any comments submitted to the docket, as appropriate.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-N-0031 for ``Vaccines and Related Biological Products; Notice
of Meeting; Establishment of a Public Docket; Request for Comments.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: Prabhakara Atreya or Lisa Wheeler,
Center for Biologics Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD

20993-0002,<PHONE_NUMBER>, respectively at [email protected]; or
FDA Advisory Committee Information Line, 1-800-741-8138<PHONE_NUMBER>
in the Washington, DC area). A notice in the Federal Register about
last-minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check FDA's website at
https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
joining the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. The committee
will meet in open session to discuss and make recommendations on the
selection of strains to be included in the influenza virus vaccines for
the 2022-2023 influenza season.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's website after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link. The meeting will include slide presentations with audio
components to allow the presentation of materials in a manner that most
closely resembles an in-person advisory committee meeting.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see
ADDRESSES) on or before February 23, 2022, will be provided to the
committee. Comments received after February 23, 2022, and by March 2,
2022, will be taken into consideration by FDA. Oral presentations from
the public will be scheduled on March 3, 2022, between approximately
1:30 p.m. and 2:30 p.m. Eastern Time. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before February 17, 2022. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by February 18, 2022.
    For press inquiries, please contact the Office of Media Affairs at
[email protected] or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Prabhakara Atreya (see FOR FURTHER INFORMATION CONTACT), at
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: January 19, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-01368 Filed 1-24-22; 8:45 am]
BILLING CODE 4164-01-P


Quantitative Usage Analysis of Lindane Analyst: Istanbul Yusuf Case #

315 AI #

9001 February 27,

2002 Lindane is used for seed treatment of small grains, field corn and sorghum.

Approximately 142,000 pounds of lindane are applied to 9. 7 million acres of small grains, corn, and sorghum. Lindane is applied at an average of 0.

0147 pounds active ingredient per acre.

The vast majority (98%)

of lindane seed treatment are incorporated in the seed on farm.

Very little is incorporated into seed by seed processors. Site Acres Grown Acres treated Wtd Average Acres treated Est.

Max %crop Treated Wtd. Avg.

%crop Treated Est. Max.

Lb ai Applied Wtd. Avg.

Lb ai Applied Est. Max.

Avg. Appl. Rate State of Most Usage Wheat/ barley 68,373,000 4,786,110 8,197,560 7%

12%

89,422 153,294 0.0187 MN, MT, KS, ND 93% Oats/ rye 5,812,000 58,120 116,240 1%

2%

843 1,685 0.0145 ND, PA 100% Corn 79,545,000 4,772,700 7,159,050 6%

9%

51,545 77,318 0.0108 KS, FL,

MD, DE, IA, MI 76% Sorghum 9,

195,000 91,950 183,900 1%

2%

331 662 0.0036 TX 100% Total/

Average 9,

708,880 15,656,750 142,141 232,960 SOURCES: EPA Proprietary Data 2001,

USDA 2001 Agricultural Statistics,

Assessment of Insecticide Use for Field Crops in North Dakota for 2000 by Glogoza,

P.

A.,

R.

Zollinger, and M.

McMullen, Kansas Agricultural Cemical Usage, Product Labels of Kernel Guard and Agrox D L plus.


[Federal Register Volume 85, Number 106 (Tuesday, June 2, 2020)]
[Proposed Rules]
[Pages 33583-33587]
[FR Doc No: 2020-11351]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2020-0493; Product Identifier 2019-CE-046-AD]
RIN 2120-AA64

Airworthiness Directives; Textron Aviation, Inc. Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: The FAA proposes to supersede Airworthiness Directive (AD)
2019-08-13 for Textron Aviation, Inc. (type certificate previously held
by Cessna Aircraft Company) Models 525, 525A, and 525B airplanes with
Tamarack active load alleviation system (ATLAS) winglets installed in
accordance with Supplemental Type Certificate (STC) SA03842NY. AD 2019-
08-13 resulted from mandatory continuing airworthiness information
(MCAI) originated by an aviation authority of another country to
identify and correct an unsafe condition on an aviation product. The
MCAI describes the unsafe condition as malfunction of the ATLAS. This
AD results from the identification of corrective actions that, if
implemented, allow operators to reactivate the ATLAS and restore
operations to normal procedures. The FAA is proposing this AD to
address the unsafe condition on these products.

DATES: The FAA must receive comments on this proposed AD by July 17,
2020.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to https://www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue SE, Washington, DC 20590, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
    For Cranfield Aerospace Solutions Limited and Tamarack Aerospace
Group service information identified in this AD, contact Cranfield
Aerospace Solutions Ltd., Cranfield, Bedford MK43 0AL, United Kingdom;
telephone: +44 1234 754 166; FAX: +44 1234 752 375; email:
<EMAIL_ADDRESS>internet: https://www.cranfieldaerospace.com/service/aircraft-modification-products/et.
You may review copies of the referenced service information at the FAA,
Airworthiness Products Section, Operational Safety Branch, 901 Locust,
Kansas City, Missouri 64106. For information on the availability of
this material at the FAA, call<PHONE_NUMBER>.

Examining the AD Docket

    You may examine the AD docket on the internet at https://www.regulations.gov by searching for and locating Docket No. FAA-2020-
0493; or in person at Docket Operations Monday through Friday, except
Federal holidays. The AD docket contains this

proposed AD, the regulatory evaluation, any comments received, and
other information. The street address for the Docket Office is listed
above. Comments will be available in the AD docket shortly after
receipt.

FOR FURTHER INFORMATION CONTACT: Steven Dzierzynski, Avionics Engineer,
FAA, New York ACO Branch, 1600 Stewart Avenue, Suite 410, Westbury, New
York 11590; telephone:<PHONE_NUMBER>; fax:<PHONE_NUMBER>; email:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Comments Invited

    The FAA invites you to send any written relevant data, views, or
arguments about this proposed AD. Send your comments to an address
listed under the ADDRESSES section. Include ``Docket No. FAA-2020-0493;
Product Identifier 2019-CE-046-AD'' at the beginning of your comments.
The FAA specifically invites comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. The
FAA will consider all comments received by the closing date and may
amend this proposed AD because of those comments.
    The FAA will post all comments received, without change, to https://regulations.gov, including any personal information you provide. The
FAA will also post a report summarizing each substantive verbal contact
received about this proposed AD.

Discussion

    The FAA issued AD 2019-08-13, Amendment 39-19634 (84 FR 24007; May
24, 2019) (``AD 2019-08-13'') for Textron Aviation, Inc. Models 525,
525A, and 525B airplanes with Tamarack ATLAS winglets installed in
accordance with STC SA03842NY. AD 2019-08-13 prohibits all flight by
revising the operating limitations in the airplane flight manual (AFM)
and fabricating and installing a placard, until a modification has been
incorporated in accordance with an FAA-approved method. AD 2019-080-13
was based on MCAI originated by the European Aviation Safety Agency
(EASA), which is the Technical Agent for the Member States of the
European Community. EASA issued AD No. 2019-0086-E, dated April 19,
2019, to address an unsafe condition related to reports of the ATLAS
malfunctioning, which could lead to loss of control of the airplane.

Actions Since AD 2019-08-13 Was Issued

    Since the FAA issued AD 2019-08-13, Cranfield Aerospace Solutions
Limited (Cranfield), the holder of STC SA03842NY, determined that
failure of the Tamarack Active Camber Surface (TACS) control units
(TCUs) was caused by a printed circuit board attachment screw coming
loose, which caused a short circuit in the TCU. EASA revised the MCAI
and issued EASA AD No. 2019-0086R1, dated August 9, 2019, to require
modifications previously developed by Cranfield to restore the safety
of the ATLAS design. Cranfield modified the TCUs with a self-locking
screw, an additional flat washer, and linear variable differential
transformer potting to prevent detachment from vibration during flight.
Cranfield also developed centering strips to modify the trailing edge
of the TACS that will return the TACS to faired when TCU power is
removed or when the TACS are ``blown'' out of position if ATLAS power
is removed.
    Installation of the modified TCU will prevent a short circuit of
the ATLAS TCU, and installation of the centering strips to the TACS
will ensure the TACS remains in a faired position in case of
inadvertent power loss to the ATLAS.
    Cranfield also revised the Tamarack maintenance manual supplement
for airplanes with the Tamarack ATLAS winglets installed to include
instructions for continued airworthiness related to the centering
strips.

Comments

    The FAA gave the public the opportunity to comment on AD 2019-08-13
and received 34 comments. The majority of the commenters were operators
and maintenance personnel. The remaining commenters included Tamarack
Aerospace Group (Tamarack) and the General Aviation Manufacturers
Association (GAMA). The following presents the relevant comments
received on AD 2019-08-13 and the FAA's response to each comment.

A. Supportive Comments

    Erin Saunders, Victor Ochoa, and an anonymous commenter support the
AD action.

B. Comments Regarding the FAA's Justification of an Unsafe Condition
Requests for a Thorough Investigation of the Issues

    Many commenters questioned or requested clarification of the FAA's
determination that there is an unsafe condition. Seven commenters
stated the FAA should have completed a more thorough investigation and
analysis of the issues. Tamarack, Advanced Jets, LLC (Advanced Jets),
and Kenneth Adelman requested the FAA consider that the data extracted
from the incident aircraft does not agree with the pilot's description
of an aggressive roll rate. John Harris, Andrew Vann, Douglas Sayre,
and five other commenters stated that the malfunction of the European
aircraft that prompted EASA's emergency AD was caused by the failure of
the operator to comply with the manufacturer's mandatory service
bulletin. These commenters noted that there have been no failures
experienced by aircraft with winglets that have complied with the
manufacturer's mandatory service bulletin. Fourteen commenters stated
they have been operating for a considerable time with the ATLAS
winglets and have not experienced any issues. These commenters further
stated that installation of the winglets increases performance, safety,
and economy and expressed support for Tamarack as a company.
    The FAA has considered the comments pertaining to the pilot's
incident report on the European airplane. At the time AD 2019-08-13 was
issued, the airplane data from the incident that prompted the EASA AD
was not available. However, the FAA analyzed the information from the
pilot's incident report and additional information received from EASA
to make the decision to issue AD 2019-08-13. Since AD 2019-08-13 was
issued, Cranfield provided data to identify the root cause of the
unsafe condition and to provide corrective action, which prompted this
superseding NPRM.
    The FAA agrees with the comments regarding the operator's failure
to comply with the manufacturer's service bulletin. However, operators
are not required to comply with manufacturer service bulletins unless
mandated by the FAA or other civil aviation authority. EASA AD No.
2019-0086-E, dated April 19, 2019, which prompted AD 2019-08-13, did
not require incorporation of the service bulletins for TCU modification
and installation of the centering strips. This NPRM proposes to require
TCU modification and installation of the centering strips using
Cranfield Aerospace Solutions Limited Service Bulletin CAS/SB1480,
Issue A, dated July 2019 (Cranfield CAS/SB1480, Issue A), which
incorporates two earlier service bulletins for those actions.
    The fact that commenters' personal experience with ATLAS winglets
has been positive does not negate the existence of an unsafe condition.
Despite any benefit to individual owners when the system operates

without failure, the FAA determined that an unsafe condition with the
ATLAS exists and requires corrective action.

Requests To Clarify the Hazard Caused by a Malfunction

    Four commenters disputed the FAA's determination that a malfunction
of the ATLAS may reduce the pilot's ability to control the airplane.
Tamarack noted that this determination conflicts with the certification
basis and system safety analysis of the design and compliance data
during certification testing. Advanced Jets stated that the ATLAS has
been shown to be safe at speeds under 140 knots even if it
malfunctions. Kenneth Adelman stated that any reduction of pilot
control when the ATLAS malfunctions is minor and was demonstrated as
safe during the original certification of the system.
    The FAA disagrees with these comments. The ATLAS complied with the
certification basis during certification testing. EASA performed the
certification flight tests, and those tests included the ``worst case''
condition where the TACS were deployed in a fully asymmetric failure
position that induces the greatest roll input. EASA determined that
case to be ``recoverable.'' However, the incident exposed a failure
mode that was not anticipated during certification, which is the basis
of this NPRM.

Requests To Clarify the FAA's Position on the Use of Speed Tape

    Kenneth Adelman, Advanced Jets, and two anonymous commenters
questioned the FAA's rejection of the use speed tape to hold the
winglets flush. These commenters noted that speed tape is a product
that is widely accepted and has been used for decades.
    The FAA disagrees. The statement in the AD regarding the use of
``speed tape'' as a corrective action to prevent movement of the TACS
during flight is based on discussions between the FAA and EASA. Speed
tape is non-structural; therefore, it cannot be relied upon to
immobilize the TACS. The corrective action in the EASA AD required
disabling the TACS. Furthermore, any modifications mandated through AD
action become changes to the type design. As explained in AD 2019-08-
13, the speed tape did not have sufficient testing and analysis to
support the type design.
    The FAA did not change this NPRM as a result of these comments.

C. Comments Regarding the NTSB Investigation

    Tamarack, Advanced Jets, GAMA, and six other commenters noted that
AD 2019-08-13 contained an incorrect statement regarding the National
Transportation Safety Board (NTSB) investigation of a fatal accident
and the role the ATLAS may have played in the accident. Most of these
commenters stated that the preliminary report released by the NTSB did
not reference the ATLAS. These commenters requested the FAA correct or
remove the statement if it is not accurate.
    The FAA agrees. The preamble language of AD 2019-08-13 contained a
statement pertaining to an NTSB investigation into a fatal airplane
accident. Although the airplane involved in the accident had the ATLAS
STC installed, since the NTSB has not released its factual report, that
statement should not have been in the preamble of AD 2019-08-13.

D. Comments Requesting the FAA Rescind the AD

    Vincent Phillips, Stanley Jobe, and CJ Holdings requested that the
AD be rescinded and the airplanes returned to service. Two of these
commenters noted that EASA has revised its emergency AD and urged the
FAA to do the same.
    The FAA partially agrees. The FAA has determined that an unsafe
condition exists on the ATLAS and that action to address the condition
is required; therefore, the FAA disagrees with rescinding the AD.
However, since AD 2019-08-13 was issued, the root cause of the failure
of the ATLAS winglets has been identified. For the reasons explained in
more detail in response to other comments, this NPRM proposes to
supersede AD 2019-08-13 to allow operation of the airplane after
modifying the ATLAS.

E. Comments Requesting Modifications to the AD

    Twelve commenters noted that Cranfield's TCU upgrade and centering
strips modification eliminate the unsafe condition. These commenters
requested the FAA allow the modifications as an alternative to the
operational prohibition of AD 2019-08-13. Richard Helms and several
other commenters stated that no aircraft with these modifications have
experienced upsets. Jerome Simon requested the FAA define an
alternative method of compliance (AMOC) so the airplanes could return
to flight.
    The FAA agrees. This NPRM proposes to supersede AD 2019-08-13.
Instead of the operational prohibition of AD 2019-08-13, this NPRM
proposes to require modification of the TCU and installation of the
centering strips on the TACS using Cranfield CAS/SB1480, Issue A, which
incorporates two earlier service bulletins for those actions. This NPRM
also proposes revising the Tamarack maintenance manual supplement to
add inspections for the centering strips.

F. Comments Regarding the Costs of Compliance

    Several commenters requested the FAA modify the cost of compliance
to include costs associated with loss of revenue from the inability to
fly the airplanes. These commenters stated that AD 2019-08-13 is
costing operators anywhere from thousands of dollars per month to
millions of dollars in total.
    The FAA disagrees. The FAA acknowledges the economic hardship for
those who depend on their airplanes for income. However, the cost
analysis in AD rulemaking actions typically includes only the actual
maintenance costs to comply with the AD and not indirect costs such as
down-time and loss of revenue.

G. Comments Requesting Clarification on Type Design Change

    GAMA requested clarification on the language in AD 2019-08-13
regarding speed tape as a type design change. GAMA questioned whether a
temporary repair while waiting for a permanent design solution should
be characterized as a type design change.
    The FAA agrees to provide clarification. The language in AD 2019-
08-13 is based on the FAA's Airworthiness Directives Legal
Interpretation, which explained that AD-mandated modifications to an
aircraft become part of the FAA-approved type design that must be
maintained as required by Sec. Sec.  39.7 and 39.9 (81 FR 24695, April
27, 2016). Regardless of whether a repair mandated by an AD is intended
to be permanent or temporary, the repair becomes a required change to
the type design unless and until the AD is superseded or rescinded or
the operator obtains an approved AMOC.

H. Comment Requesting Pilot Training

    Three commenters requested or suggested the FAA require pilot
training and familiarity with emergency procedures in the event of an
uncommanded deflection of the ATLAS in flight.
    The FAA acknowledges the commenters' request for pilot training
related to the uncommanded deflection of the ATLAS in flight. Since AD
2019-08-13 was issued, the root cause of the

failure of the ATLAS winglets has been identified. This NPRM proposes
to supersede AD 2019-08-13 to allow operation of the airplane after
modifying the ATLAS. The ATLAS modification and associated manual
revisions proposed in this NPRM are expected to mitigate the unsafe
condition without the need for additional pilot training.

I. Comment Requesting Procedure To Pull ATLAS Circuit Breaker

    Kenneth Adelman requested the FAA require adding a line item to the
abnormal/emergency section in the Tamarack Winglet AFM Supplement to
indicate that, in the event of a TCAS runaway, the circuit breaker
should be pulled.
    The FAA acknowledges the commenter's request to revise the Tamarack
Winglet AFM Supplement. As stated earlier, since AD 2019-08-13 was
issued, the root cause of the failure of the ATLAS winglets has been
identified. This NPRM proposes to supersede AD 2019-08-13 to allow
operation of the airplane after modifying the ATLAS. The ATLAS
modification and associated manual revisions proposed in this NPRM are
expected to mitigate the unsafe condition, precluding the need for the
requested AFM revision.

J. Comments Regarding the FAA's Rulemaking Process

    Two commenters questioned the FAA's decision to issue AD 2019-08-13
as an immediately effective rule without prior notice and comment.
Richard Helms stated that this decision was neither justified nor
reasonable. Advanced Jets noted that the FAA's action is not an
emergency because of the amount of time (35 days) between issuance of
EASA's emergency AD and the FAA's issuance of AD 2019-08-13.
    The FAA acknowledges the commenters' concerns that it took 35 days
to issue AD 2019-08-13 without notice and comment. The FAA worked
through the unique difficulties associated with this unsafe condition
and considered all options. The FAA coordinated with EASA and the
design approval holder before determining the best course of action to
mitigate the unsafe condition. The risk to the flying public associated
with this unsafe condition required immediate action. Allowing notice
and comment would have delayed mitigating the unsafe condition
significantly longer than 35 days. The FAA also notes that it is
proposing to supersede AD 2019-08-13 based on comments received.

Related Service Information Under 1 CFR Part 51

    The FAA reviewed the following service documents proposed for
compliance with this NPRM:
     Cranfield Aerospace Solutions Limited Service Bulletin
CAS/SB1480, Issue A, dated July 2019, which contains instructions to
ensure installation of a modified TCU and the TACS centering strips;
     Cranfield Aerospace Solutions Limited Service Bulletin
CAS/SB1475, Issue A, dated February 2019, which contains the
instructions for installing the centering strips to the TACS; and
     Tamarack Aerospace Group Cessna 525, 525A, & 525B ATLAS
Winglet Maintenance Manual Supplement, Report Number: TAG-1100-0101,
Issue G, dated September 3, 2019, which adds instructions to inspect
the centering strips and adds repetitive inspection intervals to the
Airworthiness Limitations section of the supplement for the centering
strips.
    This service information is reasonably available because the
interested parties have access to it through their normal course of
business or by the means identified in the ADDRESSES section of this
NPRM.

Other Related Service Information

    The FAA also reviewed the following documents related to this NPRM:
     Tamarack Aerospace Group ATLAS Service Bulletin SBATLAS-
57-03, dated July 27, 2018, which contains instructions to remove the
ATLAS TCU and return it to the ATLAS repair facility for modification;
     Tamarack Aerospace Group ATLAS Service Bulletin SBATLAS-
57-05, dated February 20, 2019, which contains instructions to install
centering strips on the TACS; and
     Cranfield Aerospace Solutions Limited Service Bulletin
CAS/SB1467, Issue B, dated July 2018, which contains instructions to
remove the ATLAS TCU assembly and modify it as specified in CAS/SB1480,
Issue A.

FAA's Determination and Requirements of the Proposed AD

    This product has been approved by the aviation authority of another
country, and is approved for operation in the United States. Pursuant
to our bilateral agreement with this State of Design Authority, it has
notified the FAA of the unsafe condition described in the MCAI and
service information referenced above. The FAA is proposing this AD
because it evaluated all information and determined the unsafe
condition exists and is likely to exist or develop on other products of
the same type design.

Costs of Compliance

    The FAA estimates that this proposed AD will affect 76 products of
U.S. registry. The FAA also estimates that it would take 16 work-hours
with a parts cost of $4,314 per product to modify the TCU, 24 work-
hours with a parts cost of $199 per product to install the centering
strips, and 1 work-hour per product to revise the limitations section
as proposed by this AD. The average labor rate is $85 per work-hour.
    Based on these figures, the FAA estimates the cost of the proposed
AD on U.S. operators to be $607,848, or $7,998 per product.
    According to the manufacturer, some of the costs of this proposed
AD may be covered under warranty, thereby reducing the cost impact on
affected individuals. The FAA does not control warranty coverage for
affected individuals. As a result, the FAA has included all costs in
our cost estimate.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, section 106, describes the
authority of the FAA Administrator. Subtitle VII: Aviation Programs,
describes in more detail the scope of the Agency's authority.
    The FAA is issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701: General requirements.
Under that section, Congress charges the FAA with promoting safe flight
of civil aircraft in air commerce by prescribing regulations for
practices, methods, and procedures the Administrator finds necessary
for safety in air commerce. This regulation is within the scope of that
authority because it addresses an unsafe condition that is likely to
exist or develop on products identified in this rulemaking action.

Regulatory Findings

    The FAA determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and responsibilities among the various levels of government.
    For the reasons discussed above, I certify this proposed
regulation:
    (1) Is not a ``significant regulatory action'' under Executive
Order 12866,

    (2) Will not affect intrastate aviation in Alaska, and
    (3) Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

0
1. The authority citation for part 39 continues to read as follows:

    Authority:  49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13   [Amended]

0
2. The FAA amends Sec.  39.13 by removing Airworthiness Directive (AD)
2019-08-13, Amendment 39-19634 (84 FR 24007, May 24, 2019) and adding
the following new AD:

Textron Aviation, Inc. (Type certificate previously held by Cessna
Aircraft Company): Docket No. FAA-2020-0493; Product Identifier
2019-CE-046-AD.

(a) Comments Due Date

    The FAA must receive comments by July 17, 2020.

(b) Affected ADs

    This AD replaces AD 2019-08-13, Amendment 39-19634 (84 FR 24007,
May 24, 2019) (``AD 2019-08-13'').

(c) Applicability

    This AD applies to Textron Aviation, Inc. (type certificate
previously held by Cessna Aircraft Company) Models 525, 525A, and
525B airplanes, certificated in any category, with Tamarack active
load alleviation system (ATLAS) winglets installed in accordance
with Supplemental Type Certificate SA03842NY.

(d) Subject

    Air Transport Association of America (ATA) Code 27: Flight
Controls.

(e) Reason

    This AD was prompted by mandatory continuing airworthiness
information (MCAI) issued by the aviation authority of another
country to identify and correct an unsafe condition on an aviation
product. The MCAI describes the unsafe condition as malfunction of
the ATLAS, which could cause difficulty for the pilot to recover the
airplane to safe light. The FAA is issuing this AD to prevent
malfunction of the ATLAS and to ensure the Tamarack Active Camber
Surface (TACS) remains in a faired position in the case of
inadvertent power loss to the ATLAS, which could lead to loss of
control of the airplane.

 (f) Compliance

    Unless already done, do the following actions in paragraphs (g)
and (h) of this AD.

(g) Modifications

    Before further flight after the effective date of this AD, do
the following corrective actions:
    (1) Determine whether the serial number of the TACS control unit
(TCU) assembly is listed in table 7.8. of Cranfield Aerospace
Solutions Limited (Cranfield) Service Bulletin CAS/SB1480, Issue A,
dated July 2019 (Cranfield CAS/SB1480, Issue A). If the serial
number of the TCU assembly is not listed in table 7.8., replace the
TCU assembly with a TCU assembly that has a part number listed in
section 5 and a serial number listed in table 7.8 of Cranfield CAS/
SB1480, Issue A.
    (2) Determine whether centering strips have been installed on
the trailing edge of the TACS by following step 7.4. of Cranfield
CAS/SB1480, Issue A. If the trailing edge of the TCAS does not have
centering strips, install Cranfield modification CAeM/Cessna/1475.

(h) Revision to the Maintenance Manual Supplement

    (1) Before further flight after the effective date of this AD,
revise the Airworthiness Limitations section (ALS) and Instructions
for Continued Airworthiness for your airplane by adding the updates
in Tamarack Aerospace Group Cessna 525, 525A & 525B ATLAS Winglet
Maintenance Manual Supplement, Modification CAeM/Cessna/1375/1430/
1440/1452/1475/1480, Report Number: TAG-1100-0101, Issue G, dated
September 3, 2019.
    (2) Thereafter, except as provided in paragraph (i) of this AD,
no alternative inspection intervals may be approved for the
centering strips. Inserting a later issue of the ALS with language
identical to that contained in Issue G for the centering strips is
acceptable for compliance with the requirements of this paragraph.
    (3) The AFM revision and placard required by AD 2019-08-13, if
installed, may be removed after completing the modifications
required by paragraph (g) of this AD.

(i) Alternative Methods of Compliance (AMOCs)

    The Manager, New York ACO Branch, FAA, has the authority to
approve AMOCs for this AD, if requested using the procedures found
in 14 CFR 39.19. Send information to ATTN: Program Manager,
Continued Operational Safety FAA, New York ACO Branch, 1600 Stewart
Avenue, Suite 410, Westbury, New York 11590; telephone: (516) 287-
7321; fax:<PHONE_NUMBER>; email: [email protected] Before
using any approved AMOC on any airplane to which the AMOC applies,
notify your appropriate principal inspector (PI) in the FAA Flight
Standards District Office (FSDO), or lacking a PI, your local FSDO.

(j) Related Information

    Refer to European Union Aviation Safety Agency (EASA) AD No.
2019-0086R1, dated August 9, 2019, for related information. You may
examine the MCAI on the internet at https://www.regulations.gov by
searching for and locating Docket No. FAA-2020-0493. For Cranfield
Aerospace Solutions Limited and Tamarack Aerospace Group service
information identified in this AD, contact Cranfield Aerospace
Solutions Ltd., Cranfield, Bedford MK43 0AL, United Kingdom;
telephone: +44 1234 754 166; FAX: +44 1234 752 375; email:
<EMAIL_ADDRESS>internet: https://www.cranfieldaerospace.com/service/aircraft-modification-products/et. You may review copies of the referenced service information at
the FAA, Airworthiness Products Section, Operational Safety Branch,
901 Locust, Kansas City, Missouri 64106. For information on the
availability of this material at the FAA, call<PHONE_NUMBER>.

    Issued on May 14, 2020.
Lance T. Gant,
Director, Compliance & Airworthiness Division, Aircraft Certification
Service.
[FR Doc. 2020-11351 Filed 6-1-20; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register: January 2, 2008 (Volume 73, Number 1)]
[Notices]
[Page 222-223]
[DOCID:fr02ja08-96]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket Nos. FMCSA-99-5578, FMCSA-99-5748, FMCSA-01-9258, FMCSA-02-
12844, FMCSA-03-14223, FMCSA-03-15892, FMCSA-05-21254, FMCSA-05-21711]

Qualification of Drivers; Exemption Renewals; Vision

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of final disposition.

-----------------------------------------------------------------------

SUMMARY: FMCSA previously announced its decision to renew the
exemptions from the vision requirement in the Federal Motor Carrier
Safety Regulations for 27 individuals. FMCSA has statutory authority to
exempt individuals from the vision requirement if the exemptions
granted will not compromise safety. The Agency has reviewed the
comments submitted in response to the previous announcement and
concluded that granting these exemptions will provide a level of safety
that will be equivalent to, or greater than, the level of safety
maintained without the exemptions for these commercial motor vehicle
(CMV) drivers.

FOR FURTHER INFORMATION CONTACT: Dr. Mary D. Gunnels, Director Medical
Programs Division,<PHONE_NUMBER><EMAIL_ADDRESS>FMCSA,
Department of Transportation, 1200 New Jersey Avenue, SE., Room W64-
224, Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5
p.m., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Electronic Access

    You may see all the comments online through the Federal Document
Management System (FDMS) at http://www.regulations.gov.

Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
for a 2-

year period if it finds ``such exemption would likely achieve a level
of safety that is equivalent to, or greater than, the level that would
be achieved absent such exemption.'' The statutes also allow the Agency
to renew exemptions at the end of the 2-year period. The Notice was
published on November 15, 2007. The comment period ended on December
17, 2007.

Discussion of Comments

    FMCSA received no comments in this proceeding.

Conclusion

    The Agency has not received any adverse evidence on any of these
drivers that indicates that safety is being compromised. Based upon its
evaluation of the 27 renewal applications, FMCSA renews the Federal
vision exemptions for, Thomas E. Adams, Terry J. Aldridge, Lennie D.
Baker, Jr., Grady L. Black, Jr., Jerry D. Bridges, William J. Corder,
Ralph E. Eckels, Tommy K. Floyd, Gary R. Gutschow, Richard J. Hanna,
James J. Hewitt, Carl M. Hill, Albert E. Malley, Eugene P. Martin,
Roger J. Mason, David L. Menken, Rodney M. Mimbs, Walter F. Moniowczak,
William G. Mote, James R. Murphy, Chris A. Ritenour, Ronald L. Roy,
Thomas D. Walden, Thomas E. Walsh, Kevin P. Weinhold, Charles M.
Wilkins, and Thomas A. Wise
    In accordance with 49 U.S.C. 31136(e) and 31315, each renewal
exemption will be valid for 2 years unless revoked earlier by FMCSA.
The exemption will be revoked if: (1) The person fails to comply with
the terms and conditions of the exemption; (2) the exemption has
resulted in a lower level of safety than was maintained before it was
granted; or (3) continuation of the exemption would not be consistent
with the goals and objectives of 49 U.S.C. 31136 and 31315.

    Issued on: December 27, 2007.
Larry W. Minor,
Associate Administrator for Policy and Program Development.
 [FR Doc. E7-25490 Filed 12-31-07; 8:45 am]

BILLING CODE 4910-EX-P


[Federal Register: December 18, 2007 (Volume 72, Number 242)]
[Notices]
[Page 71727-71729]
[DOCID:fr18de07-82]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-56940; File No. SR-NASDAQ-2007-095]

Self-Regulatory Organizations; The NASDAQ Stock Market LLC;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change To
Modify Fees for Members Using the Nasdaq Market Center

December 11, 2007.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder, \2\ notice is hereby given
that on November 30, 2007, The NASDAQ Stock Market LLC (``Nasdaq'')
filed with the Securities and Exchange Commission (``Commission'') the
proposed rule change as described in Items I, II, and III below, which
Items have been prepared substantially by Nasdaq. Pursuant to Section
19(b)(3)(A)(ii) of the Act \3\ and Rule 19b-4(f)(2)\4\ thereunder,
Nasdaq has designated this proposal as establishing or changing a
member due, fee, or other charge, which renders the proposed rule
change effective immediately upon filing.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 7 CFR 240.19b-4.
    \3\ 5 U.S.C. 78s(b)(3)(A)(ii).
    \4\ 7 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

    The Commission is publishing this notice to solicit comments on the
proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    Nasdaq proposes to modify pricing for Nasdaq members using the
Nasdaq Market Center. Nasdaq will implement this proposed rule change
on December 3, 2007. The text of the proposed rule change is available
at http://nasdaq.complinet.com, Nasdaq, and the Commission's Public

Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, Nasdaq included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. Nasdaq has prepared summaries, set forth in Sections A,
B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Nasdaq is proposing changes to its fees for routing odd lot and
mixed lot orders to the New York Stock Exchange (``NYSE'') and NYSE
Arca. In the case of odd lot orders routed to NYSE Arca, NYSE Arca
charges Nasdaq a fee of $0.03 per share executed for securities listed
on an exchange other than Nasdaq and a fee of $0.004 per share executed
for Nasdaq-listed securities. \5\ Nasdaq is proposing to pass these
fees through directly to its members whose orders are routed to NYSE
Arca, \6\ but only if the orders are entered into Nasdaq as odd lot
orders. Thus, if Nasdaq partially executes an order and routes a
remaining odd lot, Nasdaq's normal routing fees would apply to the odd
lot.
---------------------------------------------------------------------------

    \5\ See NYSE Arca Equities Fee Schedule (October 1, 2007)
(available at http://www.nyse.com/pdfs/NYSEArca_Equities_Fees.pdf
).

    \6\ A fee of 0.3% of the total transaction cost would apply to
orders in securities priced at less than $1 per share, which is
higher than NYSE Arca's fee for executing such orders but consistent
with Nasdaq's fee for routing other orders priced under $1.
---------------------------------------------------------------------------

    In the case of odd lot orders and the odd lot portion of partial
odd lot orders routed to NYSE, NYSE charges $0.0004 per share executed
for securities other than exchange-traded funds (``ETFs''), and charges
its regular execution fee for ETFs.\7\ However, various NYSE rules and
policies discourage the submission of odd lots to the NYSE, and Nasdaq
therefore believes that it is appropriate to use its fee schedule to
discourage the submission of routable odd lot and mixed lot orders into
Nasdaq.\8\ Specifically, in the case of an odd lot that does not check
the Nasdaq book prior to routing, Nasdaq will charge $0.03 per share
executed, while in the case of the odd lot portion of a partial round
lot that does not check the book, Nasdaq will charge $0.01 per share
executed. Nasdaq's current routing fees will remain in effect for
orders that check the book, since in these cases, the routing of the
odd lot to NYSE may be due to the order being partially executed by
Nasdaq. A fee of 0.3% of the total transaction cost will apply to
orders in securities priced at less than $1 per share.
---------------------------------------------------------------------------

    \7\ See NYSE 2007 Price List (available at http://www.nyse.com/pdfs/2007pricelist.pdf
).

    \8\ Nasdaq also notes that NYSE Arca charges $0.03 per share for
routing odd lot orders in non-Nasdaq securities, and Nasdaq's
routing fees will be equal to or lower than this level.
---------------------------------------------------------------------------

2. Statutory Basis
    Nasdaq believes that the proposed rule change is consistent with
the provisions of Section 6 of the Act,\9\ in general, and with Section
6(b)(4) of the Act,\10\ in particular, in that it provides for the
equitable allocation of reasonable dues, fees and other charges among
members and issuers and other persons using any facility or system
which Nasdaq operates or controls.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78f.
    \10\ 15 U.S.C. 78f(b)(4).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    Nasdaq does not believe that the proposed rule change will result
in any burden on competition that is not necessary or appropriate in
furtherance of the purposes of the Act, as amended.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received from Members, Participants, or Others

    Written comments were neither solicited nor received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing proposed rule change has become effective upon filing
with the Commission pursuant to Section 19(b)(3)(A)(ii) of the Act \11\
and Rule 19b-4(f)(2) thereunder,\12\ in that the proposed rule change
establishes or changes a member due, fee, or other charge imposed by
the self-regulatory organization. At any time within 60 days of the
filing of the proposed rule change, the Commission may summarily
abrogate such rule change if it appears to the Commission that such
action is necessary or appropriate in the public interest, for the
protection of investors, or otherwise in furtherance of the purposes of
the Act.
---------------------------------------------------------------------------

    \11\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \12\ 17 CFR 240.19b-4(f)(2).
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-NASDAQ-2007-095 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-NASDAQ-2007-095. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments,

all written statements with respect to the proposed rule change that
are filed with the Commission, and all written communications relating
to the proposed rule change between the Commission and any person,
other than those that may be withheld from the public in accordance
with the provisions of 5 U.S.C. 552, will be available for inspection
and copying in the Commission's Public Reference Room on official
business days between the hours of 10 a.m. and 3 p.m. Copies of such
filing also will be available for inspection and copying at the
principal office of Nasdaq. All comments received will be posted
without change; the Commission does not edit personal identifying
information from submissions. You should submit only information that
you wish to make available publicly. All submissions should refer to
File Number SR-

NASDAQ-2007-095 and should be submitted on or before January 8, 2008.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\13\
---------------------------------------------------------------------------

    \13\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
 [FR Doc. E7-24466 Filed 12-17-07; 8:45 am]

BILLING CODE 8011-01-P


Comment Info: =================

General Comment:Dear Mr. Zeller:

I am writing to request an extension of the comment period for the Food and Drug Administration's Proposed Rule Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as amended by the Family Smoking and Prevention and Tobacco Control Act (the "Proposed Rule") published at 79 Fed. Reg. 23,142 and Federal Register No. 2014-09491. I am requesting that the comment period for the Proposed Rule be extended by the FDA for an additional 105 days, from its current 75-day period, to 180 days.

I feel very strongly about e-cigarettes as being a viable alternative to smoking. Quite simply, I firmly believe that they have saved my life. The Proposed Rule raises a number of significant issues and questions that are important and relevant to me as a consumer of these products. Since I have invested much time in researching these very issues and questions, I will wish to provide and share my extensive knowledge and insight. As a consumer, this is my only (and unrealistically limited) opportunity to provide that feedback. Any conclusions formed by the FDA will be neither comprehensive nor righteous without thorough consideration of those consumers who, like myself, will be impacted by the proposed regulations.

I realize that the FDA has authority under 21 CFR 10.40 to extend this time frame and that the FDA has exercised this authority on numerous occasions in the past. I would therefore ask that you do so here, so that all stakeholders have the opportunity to provide their comments on this proposed regulation.

I appreciate your consideration of my request and am happy to discuss this issue with you further.

Sincerely, Robert Vandervennet


[Federal Register Volume 81, Number 22 (Wednesday, February 3, 2016)]
[Notices]
[Page 5728]
[FR Doc No: 2016-01952]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP15-150-000]

Columbia Gas Transmission, LLC; Notice of Availability of the
Environmental Assessment for the Proposed Line Wb2va Integrity Project

    The staff of the Federal Energy Regulatory Commission (FERC or
Commission) has prepared an environmental assessment (EA) for the Line
WB2VA Integrity Project, proposed by Columbia Gas Transmission, LLC
(Columbia) in the above-referenced docket. The Line WB2VA Integrity
Project would include modifications to Columbia's existing facilities
at 17 sites in Hardy County, West Virginia, and Shenandoah, Page,
Rockingham, and Greene Counties, Virginia. Proposed modifications
include installation of pig launchers and receivers;\1\ replacement of
short sections of existing pipeline, mainline valves, and other
appurtenant facilities; and abandonment of two existing 20-inch-
diameter pipelines beneath the South Fork of the Shenandoah River that
would be replaced with a new 24-inch-diameter pipeline. The purpose of
the project is to allow the use of modern inline inspection devices and
upgrade pipeline segments in compliance with U.S. Department of
Transportation safety standards.
---------------------------------------------------------------------------

    \1\ A ``pig'' is a tool that the pipeline company inserts into
and pushes through the pipeline for cleaning the pipeline,
conducting internal inspections, or other purposes.
---------------------------------------------------------------------------

    The EA assesses the potential environmental effects of the
construction and operation of the Line WB2VA Integrity Project in
accordance with the requirements of the National Environmental Policy
Act (NEPA). The FERC staff concludes that approval of the proposed
project, with appropriate mitigating measures, would not constitute a
major federal action significantly affecting the quality of the human
environment.
    The U.S. Army Corps of Engineers, West Virginia Department of
Natural Resources, and West Virginia Department of Environmental
Protection participated as cooperating agencies in the preparation of
the EA. Cooperating agencies have jurisdiction by law or special
expertise with respect to resources potentially affected by the
proposal and participate in the NEPA analysis.
    The FERC staff mailed copies of the EA to federal, state, and local
government representatives and agencies; elected officials;
environmental and public interest groups; Native American tribes;
potentially affected landowners and other interested individuals and
groups; and newspapers and libraries in the project area. In addition,
the EA is available for public viewing on the FERC's Web site
(www.ferc.gov) using the eLibrary link. A limited number of copies of
the EA are available for distribution and public inspection at: Federal
Energy Regulatory Commission, Public Reference Room, 888 First Street
NE., Room 2A, Washington, DC 20426,<PHONE_NUMBER>.
    Any person wishing to comment on the EA may do so. Your comments
should focus on the potential environmental effects, reasonable
alternatives, and measures to avoid or lessen environmental impacts.
The more specific your comments, the more useful they will be. To
ensure that the Commission has the opportunity to consider your
comments prior to making its decision on this project, it is important
that we receive your comments in Washington, DC on or before February
27, 2016.
    For your convenience, there are three methods you can use to file
your comments to the Commission. In all instances, please reference the
project docket number (CP15-150-000) with your submission. The
Commission encourages electronic filing of comments and has expert
staff available to assist you at<PHONE_NUMBER> or<EMAIL_ADDRESS>    (1) You can file your comments electronically using the eComment
feature on the Commission's Web site (www.ferc.gov) under the link to
Documents and Filings. This is an easy method for submitting brief,
text-only comments on a project;
    (2) You can also file your comments electronically using the
eFiling feature on the Commission's Web site (www.ferc.gov) under the
link to Documents and Filings. With eFiling, you can provide comments
in a variety of formats by attaching them as a file with your
submission. New eFiling users must first create an account by clicking
on ``eRegister.'' You must select the type of filing you are making. If
you are filing a comment on a particular project, please select
``Comment on a Filing''; or
    (3) You can file a paper copy of your comments by mailing them to
the following address: Kimberly D. Bose, Secretary, Federal Energy
Regulatory Commission, 888 First Street NE., Room 1A, Washington, DC
20426.
    Any person seeking to become a party to the proceeding must file a
motion to intervene pursuant to Rule 214 of the Commission's Rules of
Practice and Procedures (18 CFR 385.214).\2\ Only intervenors have the
right to seek rehearing of the Commission's decision. The Commission
grants affected landowners and others with environmental concerns
intervenor status upon showing good cause by stating that they have a
clear and direct interest in this proceeding which no other party can
adequately represent. Simply filing environmental comments will not
give you intervenor status, but you do not need intervenor status to
have your comments considered.
---------------------------------------------------------------------------

    \2\ See the previous discussion on the methods for filing
comments.
---------------------------------------------------------------------------

    Additional information about the project is available from the
Commission's Office of External Affairs, at (866) 208-FERC, or on the
FERC Web site (www.ferc.gov) using the eLibrary link. Click on the
eLibrary link, click on ``General Search,'' and enter the docket number
excluding the last three digits in the Docket Number field (i.e., CP15-
150). Be sure you have selected an appropriate date range. For
assistance, please contact FERC Online Support at
<EMAIL_ADDRESS>or toll free at<PHONE_NUMBER>, or for TTY,
contact<PHONE_NUMBER>. The eLibrary link also provides access to the
texts of formal documents issued by the Commission, such as orders,
notices, and rulemakings.
    In addition, the Commission offers a free service called
eSubscription which allows you to keep track of all formal issuances
and submittals in specific dockets. This can reduce the amount of time
you spend researching proceedings by automatically providing you with
notification of these filings, document summaries, and direct links to
the documents. Go to www.ferc.gov/docs-filing/esubscription.asp.

    Dated: January 28, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-01952 Filed 2-2-16; 8:45 am]
 BILLING CODE 6717-01-P